Small Molecules
9 January 2014
AstraZeneca and Bristol-Myers Squibb announce US FDA approval of FARXIGA™ (dapagliflozin)8 January 2014
Catalyst Pharmaceutical Partners Reports Positive Cardiac Safety Results of Its Phase 3 Product, Firdapse Tablets8 January 2014
Merck Receives FDA Approval for ISENTRESS® (raltegravir) for Pediatric Oral Suspension7 January 2014
Receptos Begins Enrollment of Phase 3 Trial of RPC1063 in Relapsing Multiple Sclerosis6 January 2014
RedHill Biopharma Provides Update on PK Program in Support of Ongoing RHB-104 Phase III Crohn’s Study6 January 2014
Scioderm Initiates Phase 2B Study of SD-101, A Novel Topical Therapy, for Patients with Epidermolysis Bullos6 January 2014
Kala Pharmaceuticals Announces IND Submission of its MPP-Formulated Loteprednol Etonbonate (LE-MPP) for Post-Cataract Surgery1 January 2014
BioCryst Receives Additional NIAID Funding to Advance Development of BCX4430 to Treat Marburg Virus Disease30 December 2013
OphthaliX Announces Top-Line Results of Phase III Study with CF101 for Dry Eye Syndrome30 December 2013
Veloxis Pharmaceuticals Announces NDA Submission for Envarsus® in Kidney Transplant Recipients30 December 2013
Genzyme Receives Complete Response Letter from FDA on Lemtrada™ (alemtuzumab) ApplicationNews Channels
Newsletter
La Merie Biologics
La Merie Publishing releases a weekly newsletter with a focus on biopharmaceutical research and development.
SubscribeNewsletter
New Product Alert
La Merie Publishing offers an e-mail notification service about the release of new products of La Merie Publishing. This New Product Release Alert also informs about the release of FREE reports produced by La Merie Publishing.
SubscribeFeatured reports